MedTrace Logo

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

NCT06146972 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2024-03-25

No results posted yet for this study

Summary

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease with predominantly joint involvement. To compare the efficacy and difference between elamod and tofacitib in the treatment of rheumatoid factor-positive and negative rheumatoid arthritis in RA patients with poor outcome after csDMARDs dosing, in order to better inform the clinical management.

Conditions

Interventions

DRUG

Iguratimod

Iguratimod 25mg bid + tofacitinib 5mg bid

Sponsors & Collaborators

  • Yanfeng Hou

    lead OTHER

Principal Investigators

  • Yanfeng Hou, Dr. · Yanfeng Hou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-03-24
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06146972 on ClinicalTrials.gov